BRIEF—TARGET PharmaSolutions adds Gilead to its partnership list

North Carolina, USA-based TARGET PharmaSolutions has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV.

Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner to join TARGET-Hepatitis B.

TARGET-NASH is a robust, meticulously-documented, longitudinal observational study that evaluates adult and pediatric patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

TARGET-NASH has enrolled over 4,250 patients to date and will enroll up to 15,000 patients in total over the coming years.

TARGET-NASH is led by an academic steering committee chaired by Drs Arun Sanyal (Virginia Commonwealth University); Ken Cusi (University of Florida) and Brent Tetri (Saint Louis University).

TARGET-HBV is an observational study that is evaluating patients with hepatitis B.

TARGET-HBV recently started enrolling patients and plans to enroll up to 5,000 patients across a diverse network of sites to advance our understanding of hepatitis B.